Siirry offline-tilaan Player FM avulla!
Stephen Strittmatter on a first-in-human trial for treating chronic cervical spinal cord injury
Manage episode 371715912 series 2825528
Stephen Strittmatter (Yale School of Medicine, CT, USA) discusses his first-in-human and randomised trial of a soluble Nogo-receptor-Fc decoy in patients with chronic cervical spinal cord injury. The Article is published in the August issue of The Lancet Neurology.
Read the full article:
https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00215-6/fulltext?dgcid=buzzsprout_icw_podcast_generic_laneur
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
183 jaksoa
Manage episode 371715912 series 2825528
Stephen Strittmatter (Yale School of Medicine, CT, USA) discusses his first-in-human and randomised trial of a soluble Nogo-receptor-Fc decoy in patients with chronic cervical spinal cord injury. The Article is published in the August issue of The Lancet Neurology.
Read the full article:
https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00215-6/fulltext?dgcid=buzzsprout_icw_podcast_generic_laneur
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
183 jaksoa
كل الحلقات
×Tervetuloa Player FM:n!
Player FM skannaa verkkoa löytääkseen korkealaatuisia podcasteja, joista voit nauttia juuri nyt. Se on paras podcast-sovellus ja toimii Androidilla, iPhonela, ja verkossa. Rekisteröidy sykronoidaksesi tilaukset laitteiden välillä.